



August 23, 2024

Company name: LinqMed Inc.  
Representative: Yukie Yoshii

## LinqMed received the “University Venture Award Special Prize” at the University Venture Award 2024.

CHIBA, JAPAN – August 23rd, 2024 –LinqMed Inc. (CEO Yukie Yoshii, Headquarters: Chiba-shi, Chiba, Japan, “LinqMed”), is pleased to announce that it has received the University Venture Award Special Prize at the 2024 Award for Academic Startups, sponsored by the Japan Science and Technology Agency (JST) and New Energy and Industrial Technology Development Organization (NEDO).

LinqMed was recognized for the following reasons: " LinqMed is a startup company working to develop next-generation radiopharmaceuticals that utilize the radioisotope  $^{64}\text{Cu}$  and can be used for both cancer diagnosis and treatment. This technology is expected to produce great results in clinical applications and has the potential to open up new avenues for domestically produced radiopharmaceuticals. We are also recognized for our commitment to the social implementation of an innovative, 'visible' cancer treatment drug, and for the importance of contributing to the advancement of medical technology both domestically and internationally."



“We are very honored to receive the prestigious award of the University Venture Award Special Prize. We would like to express our sincere appreciation for the great support and cooperation we have received from professors at universities and other institutions as well as from the business community. Our company was established based on research at the Quantum Science and Technology Agency (QST). We are developing cancer treatments and diagnostics using  $^{64}\text{Cu}$ , a radioactive isotope of copper, and will continue to make efforts to save many patients by bringing “innovative ‘visible’ cancer treatments” to society as soon as possible.

said **Yukie Yoshii, CEO of LinqMed.**

### **About the University-launched Venture Award**

The “University-launched Venture Award” is a system launched in 2014 to honor outstanding university-launched ventures that have started up using the results of research and development at universities and other institutions, and to commend universities and companies that have contributed to their growth.

The purpose of this award is to further promote the challenging efforts of start-ups and post-start-ups using research and development results of universities and other organizations, as well as support for university-launched ventures from universities, companies, and other organizations.

URL: <https://www.jst.go.jp/aas/>

### **About LinqMed Inc.**

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative “visible” anti-cancer treatments to patients. Our mission is “Link for Life - Linking Innovative Science and Medicine for Your Health and Happiness”. LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope  $^{64}\text{Cu}$ , which can be used for diagnosis and therapy, simultaneously.

Company Name : LinqMed Inc.

Representative: Yukie Yoshii

Location : 2-6-1 Konakadai, Inage-ku, Chiba-shi, Chiba

Establishment : July 2022

URL : <https://linqmed.co.jp/>

### **Inquiries:**

#### **LinqMed Inc.**

Email: [linqmed@linqmed.co.jp](mailto:linqmed@linqmed.co.jp)